Once-Daily NUPLAZID® (pimavanserin) 34 mg Capsule

THE PROPOSED MOA STORY*

Once-Daily NUPLAZID® (pimavanserin) 34 mg Capsule

In vitro, NUPLAZID® (pimavanserin) demonstrated no appreciable binding affinity for dopamine (including D2), histamine, muscarinic, or adrenergic receptors1

NUPLAZID® (pimavanserin) Receptor Affinity

*The precise mechanism of action of NUPLAZID in the treatment of hallucinations and delusions associated with PD psychosis is unclear. However, the effect of NUPLAZID could be mediated through a combination of inverse agonist and antagonist activity at serotonin 5-HT2A receptors and to a lesser extent at serotonin 5-HT2C receptors.
Lower Ki numbers indicate a greater binding affinity and thus a smaller amount of the drug is needed to block activity.

Proposed mechanism of action for NUPLAZID1*

Watch this video to learn more about the proposed mechanism of action for NUPLAZID.

*The precise mechanism of action of NUPLAZID in the treatment of delusions and hallucinations associated with Parkinson’s disease psychosis is unclear. However, the effect of NUPLAZID could be mediated through a combination of inverse agonist and antagonist activity at serotonin 5-HT2A receptors and to a lesser extent at serotonin 5-HT2C receptors.

For healthcare professionals